Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker

European Journal of Cancer Prevention

Volumn 18, Issue 3, 2009, Pages 220-224

  Luo, Pengcheng ^a   He, Ellen ^b,d   Eriksson, Staffan ^e   Zhou, Ji ^b   Hu, Guozhu ^c   Zhang, Jie ^a   Skog, Sven ^b,d  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b SSTK Ltd   (China)

^c Jiangxi People's Hospital   (China)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

Kidney; Renal cell carcinoma; Serum; Thymidine kinase 1; Thymidine kinase activity

Indexed keywords

ANTIBODY; THYMIDINE KINASE 1; THYMIDINE KINASE 1 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DOT HYBRIDIZATION; ENZYME ACTIVITY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIOENZYMATIC ASSAY;

ADULT; AGED; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; PROGNOSIS; THYMIDINE KINASE; TUMOR MARKERS, BIOLOGICAL;

EID: 68049135611     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e328329d817     Document Type: Article

References (21)

1. Broët P, Romain S, Daver A, Ricolleau G, Quillien V, Rallet A, et al. (2001). Thymidine kinase as a proliferative marker: clinical relevance in 1692 primary breast cancer patients. J Clin Oncol 19:2778-2787.
2. Buzaid AC, Todd MB (1989). Therapeutic options in renal cell carcinoma. Semin Oncol 16:12-16.
3. Eriksson S (2008). Exposed proliferation-related peptides, ligands and methods employing the same. PCT application, int. publ no WO2008/142664.
4. Eriksson S, Munch-Petersen B, Johansson K, Eklund H (2002). Structure and function of cellular deoxynucleoside kinases. Cell Mol Life Sci 59:1327-1346.
5. Greene FL, Page DL, Fleming ID, editors (1997). AJCC Cancer Stage Manual 5th. New York: Springer. pp. 167-178.
6. He Q, Mao Y, Wu J, Decker C, Merza M, Wang N, et al. (2004). Cytosolic thymidine kinase is a specific histopathologic tumour marker for breast carcinomas. Int J Oncol 25:945-953.
7. He Q, Fornander T, Johansson H, Johansson U, Hu GZ, Rutqvist LE, Skog S (2006). Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer. Anticancer Res 26:4753-4759.
8. Lehtinen T (1988). Correlation between tumour proliferation and serum levels of beta 2-microglobulin and thymidine kinase in malignant lymphomas. Cancer Detect Prev 12:125-131.
9. Lehtinen M, Wigren T, Lehtinen T, Lehtinen T, Kallioniemi OP, Aine R, et al. (1988). Correlation between serum tumour marker and tumour proliferation in small cell lung cancer. Tumour Biol 9:287-292.
10. Li HX, Zhang S, Lei DS, Wang XQ, Skog S, He Q (2005). Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer. Oncol Rep 13:145-149.
11. Mizutani Y, Wada H, Yoshida O, Fukushima M, Nakao M, Miki T (2003). Significance of thymidine kinase activity in renal cell carcinoma. J Urol 169:706-709.
12. Motzer RJ, Bander NH, Nanus DM (1996). Renal-cell carcinoma. N Engl J Med 335:865-875.
13. Mrstik C, Salamon J, Weber R, Stogermayer F (1992). Microscopic venous infiltration as predictor of relapse in renal cell carcinoma. J Urol 148:271-274.
14. Ozono S, Miyao N, Igarashi T, Marumo K, Nakazawa H, Fukuda M, et al. (2004). Tumor doubling time of renal cell carcinoma measured by CT. Jpn J Clin Oncol 34:82-85.
15. Poley S, Stieber P, Nüssler V, Pahl H, Fateh-Moghadam A (1997). Serum thymidine kinase in non-Hodgkin lymphomas with special regard to multiple myeloma. Anticancer Res 17:3025-3030.
16. Wu CJ, Yang RJ, Zhou J, Bao J, Zho L, Zhang P, et al. (2003). Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1. J Immunol Methods 277:157-169.
17. Wu J, Mao Y, He L, Wang N, Wu C, He Q, Skog S (2000). A new cell proliferating marker: cytosolic thymidine kinase as compared to proliferating cell nuclear antigen in patients with colorectal carcinoma. Anticancer Res 20:4815-4820.
18. Strohmeyer T, Ackermann R (1991). Classic and modern prognostic indicators in renal cell carcinoma: review of the literature. Urol Int 47:203-212.
19. Yagoda A (1989). Chemotherapy of renal cell carcinoma. Semin Urol 7:199-206.
20. Zhang J, Jia Q, Zou S, Zhang P, Zhang X, Zhang W, et al. (2006). Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients. Oncol Rep 15:455-461.
21. Zou L, Zhang PG, Zou S, Li Y, He Q (2002). The half-life of thymidine kinase 1 in serum measured by ECL dot blot: a potential marker for monitoring the response to surgery of patients with gastric cancer. Int J Biol Markers 17:135-140.